30 studies found for:    Open Studies | "Pituitary Neoplasms"
Show Display Options
Rank Status Study
21 Unknown  Comparison of Surgical Approach to Endoscopic Pituitary Adenoma Resection
Conditions: Pituitary Adenoma;   Posterior Septectomy;   Stamm Approach;   Quality of Life
Interventions: Procedure: Stamm Approach;   Procedure: Posterior Septectomy
22 Recruiting Pasireotide Therapy in Patients With Nelson's Syndrome
Condition: Nelson Syndrome
Intervention: Drug: Pasireotide
23 Unknown  Antineoplaston Therapy in Treating Patients With Brain Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
24 Recruiting A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
Condition: Acromegaly
Intervention: Drug: lanreotide
25 Recruiting An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: Pasireotide sub-cutaneous formulation
26 Recruiting Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
Conditions: Healthy;   Pituitary Disease;   Thyroid Disease
Intervention: Drug: TRH (Thyrotropin Releasing Hormone)
27 Not yet recruiting Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Condition: Brain Tumor, Recurrent
Intervention: Drug: Photofrin photodynamic therapy.
28 Recruiting Photodynamic Therapy (PDT) for Brain Tumors
Condition: Brain Tumor, Recurrent
Intervention: Drug: Photofrin (porfimer sodium) & photodynamic therapy.
29 Recruiting A Prospective Study of Outcome After Therapy for Acromegaly
Condition: Acromegaly
Intervention:
30 Recruiting Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Condition: Cushing's Disease
Interventions: Drug: Pasireotide;   Drug: Cabergoline

Show previous page of results Previous Page (1-20) Studies Shown (21-30) Next Page
Indicates status has not been verified in more than two years